Symptoms of Hematologic Tumors Patients after CAR-T Therapy: A Systematic Review and Meta-Analysis

被引:0
作者
Sun, Wan [1 ]
Wang, Shuo [1 ]
Han, Jiachen [1 ]
Zhuo, Lang [2 ]
Cao, Jiang [3 ]
Zhou, Fang [1 ]
机构
[1] Xuzhou Med Univ, Sch Nursing, 209 Tongshan Rd,Huangshan St, Xuzhou 221004, Jiangsu, Peoples R China
[2] Xuzhou Med Univ, Sch Publ Hlth, Xuzhou, Jiangsu, Peoples R China
[3] Xuzhou Med Univ, Affiliated Hosp, Dept Hematol, Xuzhou, Jiangsu, Peoples R China
关键词
Hematologic neoplasms; chimeric antigen receptor T -cell; Symptom; Meta-analysis; CELL THERAPY; DEPRESSION; NEUROTOXICITY; PREVALENCE; ANXIETY; ADULTS; BLOOD;
D O I
10.1016/j.jpainsymman.2024.11.002
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Context. Patients with hematologic neoplasms after Chimeric antigen receptor T-cell (CAR-T) therapy have multiple syndromes, with corresponding symptoms. Objectives. The review aimed to integrate the severity and incidences of symptoms in these patients, and to investigate the difference of the symptoms among different geographic locations, types of hematological tumors, evaluating instruments, and evaluating time, to provide a theoretical basis for symptom management. net, SinoMed, VIP, and WANFANG DATA was performed for studies reporting symptom scores or symptom incidences of these patients published before November 9, 2023. Heterogeneity between studies was assessed by Higgins' I2. A random effects model was used for studies with I2 > 50%. Methodological quality of included studies was assessed using the Joanna Briggs InstiResults. Eight studies were included. Among the reported symptoms, sleep disturbance, fatigue and depression were of higher severity, with the standardized scores exceeding 50. Sadness, problem with concentration, problem with memory, cough and nausea were the top five symptoms in incidence, which exceeded 50%. The symptom scores and incidences assessed by the patient-reported outcomes were higher. Within 90 days of CAR-T infusion, these patients reported a significantly higher severity and incidence of multiple symptoms. Conclusion. Patients with hematologic neoplasms treated by CAR-T suffer from multiple symptoms, including depression, fatigue, and so on. Instruments used to evaluate symptoms and the evaluating time may influence the outcome of symptom assessment. J Pain Symptom Manage 2025;69:304-317. (c) 2024 American Academy of Hospice and Palliative Medicine. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.
引用
收藏
页码:304 / 317
页数:14
相关论文
共 46 条
[1]   Gastrointestinal Adverse Events Observed After Chimeric Antigen Receptor T-Cell Therapy [J].
Abu-Sbeih, Hamzah ;
Tang, Tenglong ;
Ali, Faisal S. ;
Luo, Wenyi ;
Neelapu, Sattva S. ;
Westin, Jason R. ;
Okhuysen, Pablo C. ;
Foo, Wai Chin ;
Curry, Jonathan L. ;
Richards, David M. ;
Ge, Phillip S. ;
Wang, Yinghong .
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2019, 42 (10) :789-796
[2]   Management of cytokine release syndrome and neurotoxicity in chimeric antigen receptor (CAR) T cell therapy [J].
Acharya, Utkarsh H. ;
Dhawale, Tejaswini ;
Yun, Seongseok ;
Jacobson, Caron A. ;
Chavez, Julio C. ;
Ramos, Jorge D. ;
Appelbaum, Jacob ;
Maloney, David G. .
EXPERT REVIEW OF HEMATOLOGY, 2019, 12 (03) :195-205
[3]   How to perform a meta-analysis with R: a practical tutorial [J].
Balduzzi, Sara ;
Ruecker, Gerta ;
Schwarzer, Guido .
EVIDENCE-BASED MENTAL HEALTH, 2019, 22 (04) :153-160
[4]   Potential Pathophysiological Mechanisms Underlying Multiple Organ Dysfunction in Cytokine Release Syndrome [J].
Chen, Peixian ;
Tang, Yan ;
He, Weixin ;
Yang, Ruixuan ;
Lan, Zhien ;
Chen, Ruirong ;
Zhang, Peidong .
MEDIATORS OF INFLAMMATION, 2022, 2022
[5]   Efficacy and Safety of Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Immunoglobulin D Multiple Myeloma [J].
Chen, Wei ;
Wang, Ying ;
Qi, Kunming ;
Shi, Ming ;
Cao, Jiang ;
Bhansali, Rahul ;
Wang, Xue ;
Liu, Yang ;
Li, Hujun ;
Zhang, Huanxin ;
Yan, Zhiling ;
Sang, Wei ;
Cheng, Hai ;
Zhu, Feng ;
Sun, Haiying ;
Li, Depeng ;
Jing, Guangjun ;
Zheng, Junnian ;
Li, Zhenyu ;
Xu, Kailin .
TRANSPLANTATION AND CELLULAR THERAPY, 2021, 27 (03) :273.e1-273.e5
[6]   Cytokine Release Syndrome Biology and Management [J].
Cobb, Dustin A. ;
Lee, Daniel W. .
CANCER JOURNAL, 2021, 27 (02) :119-125
[7]   Late Events after Treatment with CD19-Targeted Chimeric Antigen Receptor Modified T Cells [J].
Cordeiro, Ana ;
Bezerra, Evandro D. ;
Hirayama, Alexandre V. ;
Hill, Joshua A. ;
Wu, Qian V. ;
Voutsinas, Jenna ;
Sorror, Mohamed L. ;
Turtle, Cameron J. ;
Maloney, David G. ;
Bar, Merav .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2020, 26 (01) :26-33
[8]   Prevalence and factors associated with anxiety and depressive symptoms among patients hospitalized with hematological malignancies after chimeric antigen receptor T-cell (CAR-T) therapy: A cross-sectional study [J].
Dai, Hongyuan ;
Xu, Shuya ;
Han, Jing ;
Li, Zhenyu ;
Cao, Jiang ;
Hu, Tingyu ;
Li, Hongxia ;
Wei, Jing ;
Dou, Xue ;
Zhou, Fang ;
Zheng, Junnian .
JOURNAL OF AFFECTIVE DISORDERS, 2021, 286 :33-39
[9]   Stability and change of emotional functioning, in late life: modelling of vulnerability profiles [J].
de Beurs, E ;
Comijs, H ;
Twisk, JWR ;
Sonnenberg, C ;
Beekman, ATF ;
Deeg, D .
JOURNAL OF AFFECTIVE DISORDERS, 2005, 84 (01) :53-62
[10]   Clinical Presentation, Risk Factors, and Outcomes of Immune Effector Cell-Associated Neurotoxicity Syndrome Following Chimeric Antigen Receptor T Cell Therapy: A Systematic Review [J].
Grant, Shakira J. ;
Grimshaw, Alyssa A. ;
Silberstein, Juliet ;
Murdaugh, Donna ;
Wildes, Tanya M. ;
Rosko, Ashley E. ;
Giri, Smith .
TRANSPLANTATION AND CELLULAR THERAPY, 2022, 28 (06) :294-302